{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:12:02Z","timestamp":1779203522045,"version":"3.51.4"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The non-steroidal mineralocorticoid receptor agonist (MRA) finerenone reduced heart failure events and cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF\/HFpEF) in a frequentist analysis of the FINEARTS-HF trial. We applied Bayesian methods including prior information to provide probabilistic estimates of efficacy and safety. The aim of this study was to estimate the probability of different magnitudes of treatment benefit with finerenone vs. placebo using Bayesian analysis of FINEARTS-HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In this pre-specified Bayesian analysis, we estimated treatment efficacy incorporating prior information in a robust meta-analytic predictive (MAP) prior using data from two finerenone trials (FIDELIO-DKD and FIGARO-DKD) and a steroidal MRA spironolactone (TOPCAT). We compared results using vague priors and informative MAP priors. The primary outcome was cardiovascular death and total heart failure events. Among 6001 patients, Bayesian analysis with vague priors confirmed the frequentist results of a reduction in the rate of the primary outcome [RR 0.83; 95% credible interval (CrI) 0.74\u20130.94]. Incorporating prior evidence increased the posterior probability of a \u2265 10% reduction in the primary event rate from 90% to 92%. The probability that finerenone reduced cardiovascular death was 80% (HR 0.93, 95% CrI: 0.79\u20131.10), and all-cause mortality was 85% (HR 0.94, 95% CrI: 0.83\u20131.06). Finerenone increased the probability of hyperkalaemia and decreased the probability of hypokalaemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The non-steroidal MRA finerenone reduced the rate of cardiovascular death and total heart failure events under both frequentist and Bayesian inference methods. The probability of benefit exceeded 80% for both cardiovascular and all-cause mortality with finerenone.<\/jats:p>\n                    <jats:p>Trial Registration: ClinicalTrials.gov Identifier: NCT04435626<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvag010","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T12:39:26Z","timestamp":1771072766000},"page":"176-185","source":"Crossref","is-referenced-by-count":0,"title":["A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HF"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8903-4906","authenticated-orcid":false,"given":"Alasdair D","family":"Henderson","sequence":"first","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow G12 8TA ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5446-9969","authenticated-orcid":false,"given":"Kieran F","family":"Docherty","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow G12 8TA ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atefeh","family":"Talebi","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow G12 8TA ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kondo","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow G12 8TA ,","place":["UK"]},{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine , Nagoya 466-8550 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-9496","authenticated-orcid":false,"given":"Mark C","family":"Petrie","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow G12 8TA ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian L","family":"Claggett","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay S","family":"Desai","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-1953","authenticated-orcid":false,"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J","family":"Atherton","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Royal Brisbane and Women\u2019s Hospital, University of Queensland Faculty of Medicine , Brisbane 4029 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Bauersachs","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hannover 30625 ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-2466","authenticated-orcid":false,"given":"Morten","family":"Schou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev-Gentofte University Hospital , Hellerup 2900 ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, St. Michael\u2019s Hospital , Toronto M5B 1W8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn S P","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore & Duke-National University of Singapore , 169609, Singapore","place":["Singapore"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-275X","authenticated-orcid":false,"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Michigan , Ann Arbor, MI 48109 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-7882","authenticated-orcid":false,"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"School of Medicine & Surgery, University Bicocca Milan , Milan 20126 ,","place":["Italy"]},{"name":"Cardiology Unit, Papa Giovanni XXIII Hospital , Bergamo 24127 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjiv J","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Northwestern University Feinberg School of Medicine , Chicago, IL 60611 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriaan A","family":"Voors","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen , Groningen 9713 GZ ,","place":["Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Inserm Clinical Investigation Centre, CHU, Universit\u00e9 de Lorraine , Nancy 54500 ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1560-9535","authenticated-orcid":false,"given":"Meike","family":"Brinker","sequence":"additional","affiliation":[{"name":"Research & Development, Pharmaceuticals, Bayer AG , Wuppertal 42096 ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flaviana","family":"Amarante","sequence":"additional","affiliation":[{"name":"Cardiology and Nephrology Clinical Development, Bayer SA , S\u00e3o Paulo 04779-900 ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Rohwedder","sequence":"additional","affiliation":[{"name":"Global Medical Affairs , Berlin 13353, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Lay-Flurrie","sequence":"additional","affiliation":[{"name":"Research & Development, Pharmaceuticals, Bayer plc , Reading RG2 6AD ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow G12 8TA ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-5317","authenticated-orcid":false,"given":"Pardeep S","family":"Jhund","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow G12 8TA ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"2026051910564466300_pvag010-B1","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0140-6736(24)01295-9","article-title":"Bayesian statistics for clinical research","volume":"404","author":"Goligher","year":"2024","journal-title":"Lancet"},{"key":"2026051910564466300_pvag010-B2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2307\/2983527","article-title":"Bayesian approaches to randomized trials","volume":"157","author":"Spiegelhalter","year":"1994","journal-title":"J R Stat Soc Ser A Stat Soc"},{"key":"2026051910564466300_pvag010-B3","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/sim.4780121504","article-title":"A case for bayesianism in clinical trials","volume":"12","author":"Berry","year":"1993","journal-title":"Stat Med"},{"key":"2026051910564466300_pvag010-B4","volume-title":"Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products: Draft guidance for industry","author":"Center for Drug Evaluation and Research","year":"2026"},{"key":"2026051910564466300_pvag010-B5","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026051910564466300_pvag010-B6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2026051910564466300_pvag010-B7","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT\u2014new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"key":"2026051910564466300_pvag010-B8","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026051910564466300_pvag010-B9","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026051910564466300_pvag010-B10","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026051910564466300_pvag010-B11","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026051910564466300_pvag010-B12","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial","volume":"26","author":"Solomon","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026051910564466300_pvag010-B13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jchf.2022.07.013","article-title":"Finerenone and heart failure outcomes by kidney function\/albuminuria in chronic kidney disease and diabetes","volume":"10","author":"Filippatos","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026051910564466300_pvag010-B14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2026051910564466300_pvag010-B15","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"key":"2026051910564466300_pvag010-B16","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/biom.12242","article-title":"Robust meta-analytic-predictive priors in clinical trials with historical control information","volume":"70","author":"Schmidli","year":"2014","journal-title":"Biometrics"},{"key":"2026051910564466300_pvag010-B17","first-page":"1","article-title":"Bayesian methods in health technology assessment: a review","volume":"4","author":"Spiegelhalter","year":"2000","journal-title":"Health Technol Assess Winch Engl"},{"key":"2026051910564466300_pvag010-B18","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1161\/CIRCULATIONAHA.121.055393","article-title":"Recommendations for statistical reporting in cardiovascular medicine: a special report from the American Heart Association","volume":"144","author":"Althouse","year":"2021","journal-title":"Circulation"},{"key":"2026051910564466300_pvag010-B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43586-020-00001-2","article-title":"Bayesian statistics and modelling","volume":"1","author":"van de Schoot","year":"2021","journal-title":"Nat Rev Methods Primer"},{"key":"2026051910564466300_pvag010-B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v080.i01","article-title":"Brms: an R package for Bayesian multilevel models using stan","volume":"80","author":"B\u00fcrkner","year":"2017","journal-title":"J Stat Softw"},{"key":"2026051910564466300_pvag010-B21","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2024"},{"key":"2026051910564466300_pvag010-B22","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v111.i09","article-title":"How to Interpret Statistical Models Using marginaleffects for R and Python","volume":"111","author":"Arel-Bundock","year":"2024","journal-title":"Journal of Statistical Software"},{"key":"2026051910564466300_pvag010-B23","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw"},{"key":"2026051910564466300_pvag010-B24","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/eurheartj\/ehaf009","article-title":"2024 revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and prevention","volume":"46","author":"J\u00fcni","year":"2025","journal-title":"Eur Heart J"},{"key":"2026051910564466300_pvag010-B25","first-page":"1415","article-title":"Bayesian analyses of cardiovascular trials\u2014bringing added value to the table","volume":"37","author":"Brophy","year":"2021","journal-title":"Can J Cardiol"},{"key":"2026051910564466300_pvag010-B26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrd1927","article-title":"Bayesian clinical trials","volume":"5","author":"Berry","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2026051910564466300_pvag010-B27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1198\/000313006X152649","article-title":"The difference between \u201csignificant\u201d and \u201cnot significant\u201d is not itself statistically significant","volume":"60","author":"Gelman","year":"2006","journal-title":"Am Stat"},{"key":"2026051910564466300_pvag010-B28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10654-016-0149-3","article-title":"Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations","volume":"31","author":"Greenland","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"2026051910564466300_pvag010-B29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA statement on p-values: context, process, and purpose","volume":"70","author":"Wasserstein","year":"2016","journal-title":"Am Stat"},{"key":"2026051910564466300_pvag010-B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00031305.2019.1583913","article-title":"Moving to a world beyond \u201cp&lt; 0.05.\u201d","volume":"73","author":"Wasserstein","year":"2019","journal-title":"Am Stat"},{"key":"2026051910564466300_pvag010-B31","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026051910564466300_pvag010-B32","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026051910564466300_pvag010-B33","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026051910564466300_pvag010-B34","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"2026051910564466300_pvag010-B35","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"2026051910564466300_pvag010-B36","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00392-024-02396-4","article-title":"Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment","volume":"113","author":"von Haehling","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"2026051910564466300_pvag010-B37","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.jacc.2024.08.033","article-title":"Why have we not been able to demonstrate reduced mortality in patients with HFmrEF\/HFpEF?","volume":"84","author":"Kondo","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026051910564466300_pvag010-B38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41573-023-00638-0","article-title":"Application of Bayesian approaches in drug development: starting a virtuous cycle","volume":"22","author":"Ruberg","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2026051910564466300_pvag010-B39","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.jclinepi.2013.02.015","article-title":"Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus","volume":"66","author":"Connor","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2026051910564466300_pvag010-B40","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.csda.2016.09.006","article-title":"A Bayesian adaptive design for clinical trials in rare diseases","volume":"113","author":"Williamson","year":"2017","journal-title":"Comput Stat Data Anal"},{"key":"2026051910564466300_pvag010-B41","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jama.2019.1198","article-title":"Post hoc Bayesian analyses","volume":"321","author":"Aberegg","year":"2019","journal-title":"JAMA"},{"key":"2026051910564466300_pvag010-B42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag010\/66938138\/pvag010.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/3\/176\/66938138\/pvag010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/3\/176\/66938138\/pvag010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:56:56Z","timestamp":1779202616000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/3\/176\/8487752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2,16]]},"published-print":{"date-parts":[[2026,5,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag010","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,2,16]]}}}